Rising incidence of sepsis worldwide, growing prevalence of disease and advancements in diagnostics market along with rising awareness among health professionals is some of the significant factor driving the global sepsis diagnostics market.
Sepsis is a life-threatening condition resulting from the immune response of the body to an infection, and timely and correct diagnosis would help improve the prognosis of sepsis patients.
The increasing prevalence of sepsis worldwide is attributed to an increase in incidence of infections, ageing population and rising burden of chronic diseases. Rapid and accurate detection enabled by molecular diagnostics and point-of-care testing is driving growth in the market.
This means the Compounded Annual Growth Rate(CAGR) is approximately 7.9% 2035. The Market will further be increasing from USD 655.7 Million in 2025 to USD 1,402.7 Million in 2035.
Key Market Metrics
| Metric | Value |
|---|---|
| Market Size in 2025 | USD 655.7 Million |
| Projected Market Size in 2035 | USD 1,402.7 Million |
| CAGR (2025 to 2035) | 7.9% |
The sepsis diagnostics market share in North America is significant, owing to the state-of-the-art healthcare infrastructure, high awareness levels, and substantial research & development spending. For example, the United States has the highest sepsis cases globally which results in the growing demand for efficient diagnostics solutions.
Additionally, the region is experiencing the growth of the market owing to the presence of major market players and the adoption of innovative technologies.
The European sepsis diagnostics market is expanding at a rapid pace owing to the increasing healthcare expenditure and very high prevalence of early disease detection. Germany, France, and the UK, for example, are taking the lead with diagnostic tools and treatment protocols to better tackle sepsis.
Data are also behind partnerships between research institutions and healthcare providers that contextualize and disseminate novel diagnostic approaches.
The Asia-Pacific region is projected to record the fastest CAGR during the forecast period, on the back of rising incidence of sepsis, improving healthcare infrastructure and increasing awareness regarding sepsis. Countries, like, China, Japan and India are also investing towards up gradation of their healthcare investment that is widening the arena of adoption of advanced diagnostic technologies.
In addition, the growing pathogen population, and rising prevalence of infectious disease in this region are expected to drive the demand for effective sepsis diagnostics.
Delayed Detection, High Testing Costs, and Variability in Clinical Practices
Early symptoms are not specific, leading to delays in diagnosis and treatment initiation, as symptoms of early stage disease may appear similar to those of other infections, are some of the key challenges for the sepsis diagnostics market.
Sepsis is still an acute condition that has high mortality and morbidity even after the algorithm is put into place due to the fact that diagnosis is often made after the gold treatment window has passed despite improvements to medicine.
Rapid diagnostic tools are often limited and high costs of molecular or biomarker-based testing limit uptake, especially in resource-poor settings. Second there are differences in clinical workflows and decision making processes between hospitals and regions, which reduces the uniformity of sepsis diagnosis and treatment.
Point-of-Care Testing, Biomarker Innovation, and AI-Powered Decision Support
The sepsis diagnostics market is growing owing to increasing global awareness regarding sepsis as a medical emergency, especially post COVID-19 pandemic. There is growing need for real time, highly sensitive diagnostic tools that can separate out sepsis from other inflammatory syndromes.
Opportunities increasing for point-of-care testing (POCT) and multiplex biomarker panels detecting combinations of procalcitonin (PCT), IL-6, C-reactive protein (CRP) and host gene expression profiles Innovations in AI-based clinical decision support systems (CDSS) are also progressing rapidly to assist physicians with interpreting complex diagnostic data and shortening the diagnostic delay.
Integration into electronic health records (EHRs) and automated alert systems is also enhancing sepsis identification and management in emergency and ICU environments.
The period from 2020 to 2024 saw increased access to hospital-acquired infections and secondary sepsis diagnostics as the COVID-19 pandemic led to higher rates of ICU admissions, necessitating additional investment in rapid diagnostics.
During this period, growth was especially apparent in blood culture alternatives, antimicrobial resistance testing, and host response assays. Yet its adoption at smaller healthcare centers was hampered by cost and training barriers. 2035: during this time frame, the market will evolve to integrated sepsis response platforms that bring together diagnostics, predictive analytics, and use of automated early warning systems.
Molecular point-of-care platforms, next-generation sequencing (NGS) and host transcriptomic profiling will become increasingly used for rapid detection of sepsis and directed treatment. Public health policies and hospital accreditation standards will drive adoption of real-time sepsis screening protocols.
Market Shifts: A Comparative Analysis 2020 to 2024 vs. 2025 to 2035
| Market Shift | 2020 to 2024 Trends |
|---|---|
| Regulatory Landscape | Expansion of emergency use authorizations and WHO guidelines |
| Consumer Trends | Focused on hospital-based blood culture testing and biomarker kits |
| Industry Adoption | Used primarily in ICUs and emergency departments |
| Supply Chain and Sourcing | Dependent on centralized lab networks |
| Market Competition | Dominated by IVD and clinical diagnostics firms |
| Market Growth Drivers | Driven by hospital-acquired infections and mortality prevention mandates |
| Sustainability and Environmental Impact | Low focus on test kit waste and single-use plastics |
| Integration of Smart Technologies | Use of alert systems and lab automation |
| Advancements in Diagnostic Tools | Improvements in blood culture time and biomarker sensitivity |
| Market Shift | 2025 to 2035 Projections |
|---|---|
| Regulatory Landscape | Establishment of mandatory hospital sepsis protocols and diagnostic accuracy benchmarks |
| Consumer Trends | Demand for non-invasive, POCT-based sepsis screens and EHR-integrated alerts |
| Industry Adoption | Broader use in ambulatory settings, urgent care, and pre-hospital triage |
| Supply Chain and Sourcing | Shift toward decentralized diagnostics, mobile test units, and cloud-based reporting |
| Market Competition | Entry of AI-health startups, wearable diagnostics companies, and NGS developers |
| Market Growth Drivers | Accelerated by value-based care models, remote diagnostics, and infection control reforms |
| Sustainability and Environmental Impact | Increased demand for recyclable diagnostic components and sustainable packaging |
| Integration of Smart Technologies | Expansion into AI-driven triage, predictive analytics, and smart monitoring dashboards |
| Advancements in Diagnostic Tools | Innovation in rapid pathogen ID panels, sepsis transcriptomics, and lab-on-a-chip devices |
The USA is the largest market for sepsis diagnostics products, due to high healthcare expenditure, clinical awareness, and widespread implementation of early warning systems and infection control protocols. Multi-analyte panels and real-time CDSS platforms increasingly adopted in the critical care environment.
| Country | CAGR (2025 to 2035) |
|---|---|
| USA | 8.0% |
NHS-led initiatives in the UK are encouraging early diagnosis by implementing standardized screening tools and accelerating the procurement of diagnostics. Collaborations across schools, biotech companies, and public hospitals are speeding the rollout of disease type-specific, AI-enhanced sepsis detection platforms.
| Country | CAGR (2025 to 2035) |
|---|---|
| UK | 7.8% |
EU countries are still investing in hospital digitization, infection surveillance and antimicrobial stewardship, driving growth in sepsis diagnostics. Integrated diagnostic workflows and next-gen PCR panels are driving an increase in treatment timelines across Germany, France and the Netherlands.
| Region | CAGR (2025 to 2035) |
|---|---|
| EU | 7.9% |
The expansion in the market is being maneuvered by Japan’s sophisticated hospital systems and a focus on the early detection of infections. Growing need for host biomarkers testing, portable diagnostics, and low-volume blood sampling kits is bolstering growth across tertiary and secondary hospitals.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 7.9% |
South Korea is adopting solutions for sepsis diagnostics in light of smart hospital projects and AI-based infection control platforms. Government support for biotech R&D and emergency response preparedness is an important driver for the demand for rapid sepsis detection technologies across public and private healthcare networks.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 8.0% |
The growing need for rapid diagnosis in life-threatening infections together with the consensus of early detection and intervention impact the sepsis diagnostics market. Sepsis is associated with high mortality worldwide and rapid diagnostics are critical in the timely initiation of therapy. On the basis of product type, diagnostic instruments and automated methods are highly used.
Access to these segments results in faster pathogen detection, antimicrobial resistance profiling, and data-driven decision-making all of which play important roles in improving clinical outcomes.Their use in automated and instrument-based diagnostics to support sepsis care protocols in acute and emergency settings is increasingly pivotal for global healthcare systems striving to reduce ICU stays, lower mortality rates and combat antimicrobial resistance.
| Product Type | Market Share (2025) |
|---|---|
| Instrument | 64.2% |
Diagnostics account for the sepsis diagnostics market, owing to the rapid identification that instruments can offer for pathogens, biomarkers, and antibiotic susceptibility to provide results within hours. These platforms shorten diagnostic delays and inform clinicians earlier to make treatment decisions in emergent and intensive care settings.
The prominent technologies used are PCR-based analyzers, immunoassay systems, and blood culture instruments (with continuous monitoring). Instruments enable multiplex testing, reducing the need for repeated sampling, and increasing throughput in high-volume hospital labs.
Other emerging point-of-care (POC) devices allow rapid lactate and procalcitonin-testing at the bedside. These functionalities lead to accelerated triage and risk stratification for patients who come in with signs of sepsis.
Although blood culture media is still crucial for microbial growth and phenotypic confirmation, instruments dominate with respect to diagnostic speed and are promoted predominantly in protocol-driven hospitals where early goal-directed therapy is a high priority.
Automated diagnostics account for a dominant share of the sepsis diagnostics market owing to their penetration in automating the laboratory processes, improving the accuracy of detection, and offering quicker clinical insights.
Such systems mitigate risks of human error, make standardized values available to all approvers and provide seamless integration to electronic health records (EHRs) for the clinician’s response.
Automation enables fast sample processing, round-the-clock lab operation, and smart alert systems monitoring for sudden critical values. In recent years, many systems have been developed using machine learning algorithms to predict early sepsis using the trends in biomarker data and vitals of a patient.
Automated platforms are scaled for the needs of a mass population, offering infection control benefits, as well as supporting antimicrobial stewardship initiatives, and are therefore a preferred of hospitals. These technologies help decrease turnaround time from days to hours, a crucial factor in sepsis survival.
While conventional modalities such as manual microscopy and culture approaches remain important confirmatory tools, they are being increasingly augmented, and in some cases, supplanted, by automated diagnostics for front-line screening and real-time decision-making.
Technological innovations in sepsis diagnostics are being embraced within an exhaustive range of end-users like emergency departments, ICUs, and clinical laboratories that are focused on rapid detection, antimicrobial stewardship, and infection-related patient results.
Increased sepsis-related mortality and rapid evolution of global prioritization for rapid diagnostic tools will promote innovation in molecular assay, host-response biomarker, and AI-powered decision support interface.
Fortunes are being spent on point-of-care (POC) testing, multiplex PCR platforms, and integrated digital triage technologies. Speed-to-result, diagnostic accuracy, and antibiotic resistance management are key focus areas for diagnostics leaders and precision medicine startups alike.
Market Share Analysis by Key Players & Sepsis Diagnostics Providers
| Company Name | Estimated Market Share (%) |
|---|---|
| bioMérieux SA | 14-18% |
| Roche Diagnostics | 12-16% |
| Thermo Fisher Scientific Inc. | 10-14% |
| Danaher Corporation (Beckman Coulter) | 8-12% |
| Immunexpress Inc. | 6-9% |
| Other Sepsis Diagnostic Developers | 30-40% |
| Company Name | Key Offerings/Activities |
|---|---|
| bioMérieux SA | In 2024 , launched the VITEK® REVEAL system for rapid antimicrobial susceptibility testing in bloodstream infections; in 2025 , expanded its VIDAS® BRAHM S PCT assay for early sepsis risk stratification. |
| Roche Diagnostics | Released cobas® SeptiScore Panel in 2024 for differentiating bacterial vs. viral sepsis causes; in 2025 , introduced AI-powered sepsis alert integration for hospitals using cobas® Liat platforms. |
| Thermo Fisher Scientific Inc. | Launched a high-sensitivity multiplex qPCR assay for sepsis pathogen panels in 2024 ; in 2025 , developed a host-response biomarker index based on gene expression profiling. |
| Danaher Corporation (Beckman Coulter) | In 2024 , added monocyte distribution width (MDW) to routine CBC workflow for early sepsis screening; in 2025 , integrated automated sepsis flags into hematology analyzers. |
| Immunexpress Inc. | Commercialized SeptiCyte® RAPID globally in 2024 for use with Biocartis’ Idylla™ platform; in 2025 , initiated clinical deployment of host gene signature testing at the point of care. |
Key Market Insights
bioMérieux SA (14-18%)
bioMérieux remains a global leader in sepsis diagnostics with deep expertise in pathogen identification and PCT-based infection monitoring. Its 2024 to 2025 portfolio upgrades enhance early sepsis detection and treatment optimization.
Roche Diagnostics (12-16%)
Roche focuses on host-response profiling and AI-powered clinical workflows. Its 2024 to 2025 diagnostics tools improve differentiation and enable automated, actionable insights at the hospital bedside.
Thermo Fisher Scientific Inc. (10-14%)
Thermo Fisher delivers pathogen and immune response solutions through molecular diagnostics. Its 2025 advancements in sepsis gene expression profiling move diagnostics toward precision-based sepsis care.
Danaher Corporation (Beckman Coulter) (8-12%)
Danaher brings sepsis screening to routine lab testing. The MDW parameter and 2025 automation enhancements make early detection feasible across a broader spectrum of care settings.
Immunexpress Inc. (6-9%)
Immunexpress pioneers host-response diagnostics with the SeptiCyte® platform. Its 2024 to 2025 expansion into point-of-care genomics positions it at the forefront of rapid, non-pathogen-specific sepsis detection.
Other Key Players (30-40% Combined)
Numerous diagnostics firms and medtech innovators are improving speed, sensitivity, and clinical integration of sepsis detection. These include:
The overall market size for the sepsis diagnostics market was USD 655.7 Million in 2025.
The sepsis diagnostics market is expected to reach USD 1,402.7 Million in 2035.
The demand for sepsis diagnostics is rising due to increasing global sepsis incidence, growing awareness of early detection, and advancements in automated diagnostic tools. Rapid identification of bloodstream infections and improved clinical outcomes through early intervention are further fueling market growth.
The top 5 countries driving the development of the sepsis diagnostics market are the USA, Germany, China, Japan, and the UK
Instruments and automated diagnostics are expected to command a significant share over the assessment period.
Explore In-vitro Diagnostics Devices Insights
Sepsis Diagnostics Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
